One-month treatment with Hemlibra (emicizumab) and an immunosuppressive medication were effective for patients with acquired hemophilia at rapidly controlling bleeding and reducing the use of other therapies, a single-center study shows. The researchers also noted that using less toxic immunosuppressive agents such as rituximab was effective at blocking…
Search results for:
Hemophilia is a rare genetic disorder preventing proper blood clotting, primarily affecting men, with types A and B being most common. Hemlibra (emicizumab), an antibody-based therapy mimicking factor VIII activity, effectively controls bleeding in acquired hemophilia and is safe for children with hemophilia A. GreenGene F, a lab-made factor VIII, is also approved in China for hemophilia A prophylaxis.
AI-generated summaries are for informational use only, based on content from multiple pages. They may not reflect full context. For complete details, see the original sources. Consult a qualified healthcare professional for medical advice.
GreenGene F (beroctocog alfa), a lab-made version of coagulation factor VIII, has been approved by regulators in China for the control and prevention, or prophylaxis, of bleeding episodes associated with hemophilia A, the therapy’s developer, GC Pharma,  announced. GreenGene F will be available in China in the first…
Switching to Hemlibra (emicizumab) was safe and effective in children with hemophilia A, including in those who had been minimally treated before or who had not been treated at all, a real-world study reported. Researchers noted that studies involving a larger number of patients are still warranted to…
Hemophilia is a rare disorder in which a person’s blood is not able to clot properly, resulting in unusually easy and prolonged bleeding.
Social Clips
7 Recommended Books to Learn More About Hemophilia
Hemophilia is a genetic disorder that prevents blood clotting. Most common in men, there are two main types of hemophilia: hemophilia A and B. Below is a curated list of recommended reads for family members, friends and carers of patients with hemophilia, with help from Good Reads and Alibris.
There are several types of hemophilia, a rare bleeding disorder wherein the blood fails to clot properly. Hemophilia A and B are the most common types, while hemophilia C is comparatively rare.
In the U.S., hemophilia A is estimated to affect one in every 5,000 male births, hemophilia B one in 25,000 male births, and hemophilia C one in every 100,000 people (males and females). Hemophilia A is thus four times more common than hemophilia B, and about 10 times more common than…
Hemophilia, a disorder characterized by excessive bleeding, is caused by the lack of activity of certain clotting factors, which are proteins that are needed to form blood clots.
Social Clips
Explaining Hemophilia A and B
https://www.youtube.com/watch?v=S_YMGmHqIW4 This video from Claire Blatt shares a lecture about the effects of two blood-clotting disorders: hemophilia A and hemophilia B. MORE: A study shows that NovoSeven counters bleeding in children with hemophilia. Though the lecture is aimed at nurses, it’s helpful for anyone looking to learn about these…
Hemophilia is a rare disorder in which the blood doesn’t clot properly, resulting in the disease’s hallmark symptoms of bleeds — excessive bleeding that extends over a prolonged period of time — that in turn leads to other complications.